Key Drivers
- Strong liquidity
- High profitability
- Working‑capital risk
AIAI Summary
ResMed's investment thesis now hinges less on cyclical device volume and more on converting a margin-rich, recurring‑revenue model via RCS/software and distribution automation — if management can demonstrate clear ARR growth and earlier-than-expected fulfillment cost savings, upside is meaningful, but failure to scale SaaS or demand erosion from GLP‑1s/competitive pressure would likely compress the premium multiple.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong liquidity
- •High profitability
- •Working‑capital risk
RMD combines strong liquidity, high margins, conservative leverage and robust free cash flow that support dividends and low financial risk, but concentrated intangibles, receivables and inventory warrant close monitoring.
Price Behavior
Key Price Behavior Insights:
- •Below moving average
- •Deeply oversold
- •Lower highs trend
Price is in a short-term downtrend—closing at $225.99 well below the last month's $246 average, deeply oversold (RSI ~22), with near-term support $225–$230 (secondary $232.41) and resistance $252–$259 (reclaiming ~$246 needed to revive momentum).
Clear break below the last month average with pronounced recent losses indicating strong selling pressure
Sentiment & News
Key News Insights:
- •U.S. distribution
- •Institutional repositioning
- •Analyst upgrades
ResMed is expanding U.S. distribution capacity, drawing mixed but active institutional flows and modestly bullish analyst revisions while shares trade technically oversold after a near-term pullback.
The expansion and fresh analyst optimism support medium-term growth prospects, while active repositioning and oversold technicals could spur a near-term rebound
Similar Companies in Healthcare
Other companies in the same sector with AI ratings